Antiviral Response of HCV Genotype 1 to Consensus Interferon and Ribavirin Versus Pegylated Interferon and Ribavirin
- 148 Downloads
Achieving an antiviral response at a reasonable cost is a challenge in the treatment of patients with chronic hepatitis C. A previous study indicated that consensus interferon with ribavirin had promising activity against hepatitis C virus (HCV) genotype 1. The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon α-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1. Intention-to-treat analysis showed response in 37% and 41% of subjects treated with consensus interferon/ribavirin or pegylated interferon/ribavirin, respectively, with response rates of 42% and 44% observed in analysis of the per-protocol population, not a significant difference. Tolerability of the two treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. It is possible that if consensus interferon is administered daily rather than three times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1.
KeywordsViral hepatitis Viral load Depression Quality of life African-American Interferon alfacon-1
This work was supported in part by a grant from InterMune.
- 24.Blatt LM, Radhakrishnan R, Seiwert S, Tan H, Cheung E (2005) Biological characterization of PEG alfacon-1 in vitro: comparison of biological potency to the parent molecule interferon alfacon-1. Gastroenterology 128:S915Google Scholar